Éva Remenár

10.8k total citations · 2 hit papers
64 papers, 5.0k citations indexed

About

Éva Remenár is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Éva Remenár has authored 64 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Otorhinolaryngology, 26 papers in Oncology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Éva Remenár's work include Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer Diagnosis and Treatment (8 papers). Éva Remenár is often cited by papers focused on Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer Diagnosis and Treatment (8 papers). Éva Remenár collaborates with scholars based in Hungary, Belgium and Spain. Éva Remenár's co-authors include Ricard Mesı́a, Didier Cupissol, Andrzej Kawecki, Sylvie Rottey, Ricardo Hitt, Marco Benasso, Frédéric Peyrade, Jan B. Vermorken, Carsten Bokemeyer and Nadia Amellal and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Éva Remenár

60 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Jan B. Vermorken, Ricard Mesı́a et al. New England Journal of Medicine profile →
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

2007 1.2k citations Jan B. Vermorken, Éva Remenár et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éva Remenár Hungary	21	2.9k	2.7k	2.0k	1.8k	1.1k	64	5.0k
D. De Raucourt France	22	2.8k 1.0×	2.2k 0.8×	1.9k 0.9×	1.9k 1.0×	787 0.7×	55	4.4k
F. Cognetti Italy	27	2.2k 0.8×	2.3k 0.9×	1.3k 0.7×	1.9k 1.1×	933 0.9×	129	4.8k
Marco Benasso Italy	16	2.1k 0.7×	2.0k 0.8×	1.6k 0.8×	1.2k 0.7×	759 0.7×	67	3.7k
Ricardo Hitt Spain	28	3.5k 1.2×	4.0k 1.5×	2.9k 1.4×	2.0k 1.1×	1.5k 1.3×	69	6.7k
Armin Schueler Germany	11	1.8k 0.6×	2.2k 0.8×	1.6k 0.8×	962 0.5×	962 0.9×	18	3.8k
Scott Saxman United States	21	2.2k 0.8×	2.5k 0.9×	1.5k 0.8×	2.4k 1.3×	1.2k 1.1×	41	5.5k
Roger Ove United States	11	1.7k 0.6×	2.0k 0.7×	1.7k 0.9×	1.1k 0.6×	978 0.9×	36	4.1k
Ranjan Sur Canada	18	2.6k 0.9×	3.0k 1.1×	3.0k 1.5×	2.2k 1.2×	1.3k 1.2×	68	6.4k
Jan B. Vermorken Belgium	35	2.1k 0.7×	2.2k 0.8×	1.6k 0.8×	2.3k 1.2×	731 0.7×	96	5.6k
Stéphane Temam France	33	1.8k 0.6×	2.0k 0.8×	912 0.5×	1.8k 1.0×	947 0.9×	173	4.2k

Countries citing papers authored by Éva Remenár

Since Specialization

Citations

This map shows the geographic impact of Éva Remenár's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éva Remenár with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éva Remenár more than expected).

Fields of papers citing papers by Éva Remenár

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éva Remenár. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éva Remenár. The network helps show where Éva Remenár may publish in the future.

Co-authorship network of co-authors of Éva Remenár

This figure shows the co-authorship network connecting the top 25 collaborators of Éva Remenár. A scholar is included among the top collaborators of Éva Remenár based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éva Remenár. Éva Remenár is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cserepes, Mihály, Dóra Türk, Erzsébet Rásó, et al.. (2022). EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. Cancers. 14(10). 2407–2407. 4 indexed citations

Szturz, Petr, Éva Remenár, Carla M.L. van Herpen, et al.. (2021). Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients. European Journal of Cancer. 156. 109–118. 3 indexed citations

Förster, Martin, Magnus T. Dillon, Judit Kocsis, et al.. (2019). Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. European Journal of Cancer. 123. 36–47. 22 indexed citations

Soulières, Denis, Lisa Licitra, Ricard Mesı́a, et al.. (2018). Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clinical Cancer Research. 24(11). 2505–2516. 34 indexed citations

Specenier, Pol, Éva Remenár, Jan Buter, et al.. (2017). TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Annals of Oncology. 28(9). 2219–2224. 12 indexed citations

Fortpied, Catherine, George Koutsodontis, Margaritis Avgeris, et al.. (2017). Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Annals of Oncology. 28(9). 2213–2218. 11 indexed citations

Gődény, Mária, Zsolt Lengyel, Zoltán Takácsi Nagy, et al.. (2016). Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis. Cancer Imaging. 16(1). 38–38. 17 indexed citations

Hitre, Erika, Barna Budai, Zoltán Takácsi‐Nagy, et al.. (2013). Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. British Journal of Cancer. 109(5). 1117–1122. 54 indexed citations

Harrington, Kevin J., Martin Robinson, Éva Remenár, et al.. (2012). Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer. 49(7). 1609–1618. 89 indexed citations

10.

Herpen, Carla M.L. van, Murielle Mauer, Ricard Mesı́a, et al.. (2010). Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). British Journal of Cancer. 103(8). 1173–1181. 39 indexed citations

11.

Licitra, Lisa, Ricard Mesı́a, Fernando Rivera, et al.. (2010). Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Annals of Oncology. 22(5). 1078–1087. 178 indexed citations

12.

Remenár, Éva. (2009). Citogenetikai és hormonális változások fej-nyaki laphámrákos betegekben: potenciális biomarkerek a funkciómegtartó onkológiai sebészet számára. PubMed. 53(2). 157–164. 1 indexed citations

13.

Gundy, S., et al.. (2008). Biomarkerek alkalmazása során felmerülő problémák malignus és nem malignus betegségben szenvedő alkoholisták esetében. PubMed. 52(2). 153–161. 1 indexed citations

14.

Vermorken, Jan B., Ricard Mesı́a, Fernando Rivera, et al.. (2008). Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. New England Journal of Medicine. 359(11). 1116–1127. 2594 indexed citations breakdown →

15.

Remenár, Éva, et al.. (2007). Increase of hypophyseal hormone levels in male head and neck cancer patients. Pathology & Oncology Research. 13(4). 341–344. 7 indexed citations

16.

Székely, Gábor J., Éva Remenár, Miklós Kásler, & S. Gundy. (2005). Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis. 20(5). 381–385. 16 indexed citations

17.

Vermorken, Jan B., Éva Remenár, C. van Herpen, et al.. (2004). Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Journal of Clinical Oncology. 22(14_suppl). 5508–5508. 75 indexed citations

18.

Tı́már, József, Balázs Döme, Andrea Ladányi, et al.. (2003). The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer—A Multicenter Phase I/II Clinical Trial. The Laryngoscope. 113(12). 2206–2217. 16 indexed citations

19.

Lövey, József, et al.. (2003). Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiotherapy and Oncology. 68(2). 171–174. 18 indexed citations

20.

Csuka, Orsolya, et al.. (1997). Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathology & Oncology Research. 3(3). 204–210. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact